These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 9309534)

  • 1. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy.
    Custro N; Montalto G; Scafidi V; Soresi M; Gallo S; Tripi S; Notarbartolo A
    J Endocrinol Invest; 1997; 20(7):374-80. PubMed ID: 9309534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.
    Chung YH; Shong YK
    Am J Gastroenterol; 1993 Feb; 88(2):244-7. PubMed ID: 8424429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy.
    Marazuela M; García-Buey L; González-Fernández B; García-Monzón C; Arranz A; Borque MJ; Moreno-Otero R
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):635-42. PubMed ID: 8759175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
    Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
    Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a.
    Preziati D; La Rosa L; Covini G; Marcelli R; Rescalli S; Persani L; Del Ninno E; Meroni PL; Colombo M; Beck-Peccoz P
    Eur J Endocrinol; 1995 May; 132(5):587-93. PubMed ID: 7749499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
    Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type-1 interferons for HCV-related chronic hepatitis: a prospective study.
    Mazziotti G; Sorvillo F; Stornaiuolo G; Rotondi M; Morisco F; Ruberto M; Cioffi M; Amato G; Caporaso N; Gaeta GB; Carella C
    J Endocrinol Invest; 2002; 25(7):624-30. PubMed ID: 12150338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thyroid function and autoimmunity in 215 patients seropositive for the hepatitis C virus].
    Nduwayo L; Bacq Y; Valat C; Goudeau A; Lecomte P
    Ann Endocrinol (Paris); 1998 Apr; 59(1):9-13. PubMed ID: 9752392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis.
    Rotondi M; Oliviero A; Profice P; Mone CM; Biondi B; Del Buono A; Mazziotti G; Sinisi AM; Bellastella A; Carella C
    J Endocrinol Invest; 1998 Dec; 21(11):748-52. PubMed ID: 9972674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of interferon-alpha-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment.
    Carella C; Mazziotti G; Morisco F; Manganella G; Rotondi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
    J Clin Endocrinol Metab; 2001 May; 86(5):1925-9. PubMed ID: 11344186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha.
    Roti E; Minelli R; Giuberti T; Marchelli S; Schianchi C; Gardini E; Salvi M; Fiaccadori F; Ugolotti G; Neri TM; Braverman LE
    Am J Med; 1996 Nov; 101(5):482-7. PubMed ID: 8948271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.
    Murakami T; Masumoto T; Michitaka K; Horiike N; Hino H; Okada S; Kitai K; Onji M
    J Gastroenterol Hepatol; 1995; 10(5):528-31. PubMed ID: 8963028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
    Kee KM; Lee CM; Wang JH; Tung HD; Changchien CS; Lu SN; Wang PW
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):319-26. PubMed ID: 16460494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological markers of autoimmunity in renal transplant patients before and after alpha-interferon therapy for chronic hepatitis C.
    Rostaing L; Oksman F; Izopet J; Baron E; Cisterne JM; Hoff M; Abbal M; Durand D
    Am J Nephrol; 1996; 16(6):478-83. PubMed ID: 8955758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy.
    Dalgard O; Bjøro K; Hellum K; Myrvang B; Bjøro T; Haug E; Bell H
    J Intern Med; 2002 May; 251(5):400-6. PubMed ID: 11982739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy.
    Deutsch M; Dourakis S; Manesis EK; Gioustozi A; Hess G; Horsch A; Hadziyannis S
    Hepatology; 1997 Jul; 26(1):206-10. PubMed ID: 9214471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha-induced thyroid dysfunction in patients with chronic active hepatitis C: a transient, reversible and self-limited dysfunction.
    Tsuboi K; Katayama M; Yuasa R; Matoba H; Nagayama T; Ihara F; Ooya T; Matsuo K; Otsuka S; Miyachi Y
    Intern Med; 1998 Jan; 37(1):27-31. PubMed ID: 9510396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of endocrine autoantibodies in chronic hepatitis C, before and after interferon-alpha therapy.
    Murdolo G; Francisci D; Forini F; Baldelli F; Angeletti G; Stagni G; Santeusanio F; Calcinaro F; Falorni A
    J Endocrinol Invest; 2002 Dec; 25(11):938-46. PubMed ID: 12553552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.
    Fernandez-Soto L; Gonzalez A; Escobar-Jimenez F; Vazquez R; Ocete E; Olea N; Salmeron J
    Arch Intern Med; 1998 Jul; 158(13):1445-8. PubMed ID: 9665354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.